Ocular Therapeutix, Inc. (OCUL) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	52.1M	51.8M	63.7M	58.4M	51.5M
Cost of Revenue	6.7M	6.6M	5.6M	5.3M	4.5M
Gross Profit	45.3M	45.2M	58.1M	53.2M	47.0M
Operating Expenses
R&D Expense	223.5M	197.1M	127.6M	61.1M	53.5M
SG&A Expense	135.7M	118.3M	102.2M	74.5M	72.1M
General & Admin Expense	75.8M	64.4M	60.7M	33.9M	68.0M
Selling & Marketing Expense	59.9M	53.9M	41.6M	40.5M	4.2M
Other Expenses	—	—	—	—	—
Total Operating Expenses	359.3M	315.4M	229.9M	135.5M	125.6M
Cost and Expenses	366.0M	322.0M	235.5M	140.8M	130.1M
Operating Income (EBIT)	(313.9M)	(270.0M)	(171.8M)	(82.4M)	(78.7M)
Non-Operating
Interest Income	22.6M	18.4M	20.3M	4.0M	798.0K
Interest Expense	11.4M	11.8M	13.6M	11.3M	7.0M
Net Interest Income	11.2M	6.5M	6.7M	(7.4M)	(6.2M)
Other Non-Op Income/Expense	12.5M	4.1M	(21.7M)	1.6M	7.6M
Non-Operating Income (excl Interest)	(23.9M)	(15.9M)	8.1M	(13.0M)	(14.6M)
EBT (Pre-Tax Income)	(301.4M)	(265.9M)	(193.5M)	(80.7M)	(71.0M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(301.4M)	(265.9M)	(193.5M)	(80.7M)	(71.0M)
Earnings from Cont. Ops	(301.4M)	(265.9M)	(193.5M)	(80.7M)	(71.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(301.4M)	(265.9M)	(193.5M)	(87.0M)	(80.3M)
Per Share
Basic EPS	($1.42)	($1.42)	($1.22)	($1.09)	($1.04)
Diluted EPS	($1.42)	($1.42)	($1.22)	($1.02)	($0.97)
Revenue Per Share	$0.23	$0.28	$0.40	$0.73	$0.67
Shares
Basic Shares Outstanding	225.0M	187.2M	158.3M	79.8M	76.9M
Diluted Shares Outstanding	225.0M	187.2M	158.3M	85.6M	82.6M
Profitability Metrics
EBITDA	(284.6M)	(249.8M)	(176.1M)	(66.4M)	(61.9M)
D&A	5.5M	4.3M	3.8M	3.0M	2.1M
EBIT	(290.0M)	(254.1M)	(179.9M)	(69.4M)	(64.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026